Document 0790
 DOCN  M9480790
 TI    Methylprednisolone bolus: a novel therapy for severe atopic dermatitis.
 DT    9410
 AU    Galli E; Chini L; Moschese V; Paone F; Menichelli A; Fraioli G; Rossi P;
       Institute of Paediatrics, University of Rome Tor Vergata, Italy.
 SO    Acta Paediatr. 1994 Mar;83(3):315-7. Unique Identifier : AIDSLINE
       MED/94312804
 AB    Seven children suffering from severe atopic dermatitis, unresponsive to
       standard therapy, received an iv bolus dose of methylprednisolone (20
       mg/kg/day) for three days. Immunological parameters were evaluated
       before and after treatment. At the end of bolus therapy both skin
       lesions and itching improved for several months in five of seven
       patients. No side effects were observed, but a significant and transient
       lymphopenic response occurred, with lower CD4+ than CD8+ lymphocyte
       counts. Our data suggest that this therapy may be a novel and safe
       therapeutic approach in severe atopic dermatitis.
 DE    Adolescence  Child  Child, Preschool  CD4-CD8 Ratio  Dermatitis,
       Atopic/*DRUG THERAPY/IMMUNOLOGY  Female  Human  Immunoglobulins/ANALYSIS
       Injections, Intravenous  Male  Methylprednisolone/*ADMINISTRATION &
       DOSAGE  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).